CJC-1295 No DAC

Mechanism

CJC-1295 No DAC (also called Mod GRF 1-29) is a modified version of your body's natural growth hormone releasing hormone that stimulates the pituitary gland to produce and release growth hormone in natural pulses. Unlike the DAC version which creates a continuous elevation, the No DAC form produces a shorter burst that more closely mimics your body's natural growth hormone rhythm, typically lasting 30 minutes to a few hours. It is commonly combined with a GHRP like Ipamorelin to amplify growth hormone release for benefits including improved body composition, recovery, sleep quality, and skin health.

Effects

## Endocrine/GH Axis [Tier 1 - Human Data] - Modified growth hormone-releasing factor (modified GRF 1-29) with four amino acid substitutions for DPP-IV resistance - Half-life approximately 30 minutes (vs. seconds for native GHRH), allowing meaningful GH pulse amplification after a single injection - Amplifies endogenous GH pulsatility rather than creating flat-line GH elevation (preserves physiological GH rhythm) - Stimulates GH release 2-3x above baseline in a single pulse, peaking at 15-30 minutes post-injection and returning to baseline within 2-3 hours - Does NOT override somatostatin negative feedback — a critical safety feature distinguishing it from exogenous GH - Synergistic with ghrelin mimetics (ipamorelin, GHRP-2): GHRH + GHRP together produce 3-10x the GH release of either alone ## Metabolic System [Tier 2 - Clinical Observation/Small Trials] - IGF-1 elevation of 30-80% above baseline after 4-8 weeks of daily use, typically remaining within reference range - Enhanced lipolysis (growth hormone is the most potent endogenous lipolytic hormone) — preferential visceral fat mobilization - Improved fasting glucose and insulin sensitivity through GH-mediated hepatic glucose output effects - Does NOT significantly affect cortisol, prolactin, or thyroid hormones (unlike GHRP-6 or hexarelin) ## Musculoskeletal System [Tier 2 - Clinical Observation] - Enhanced collagen synthesis and connective tissue repair through IGF-1 mediated fibroblast stimulation - Improved recovery from resistance training: reduced DOMS duration and intensity reported by clinic patients - Does not directly build muscle — muscle gains are indirect through improved recovery, sleep, and GH-mediated protein synthesis support - Potential for improved bone mineral density with long-term use (GH/IGF-1 axis is critical for bone remodeling) ## Central Nervous System [Tier 2 - Clinical Observation] - Improved deep sleep (slow wave sleep) — GH release during sleep becomes more pronounced, reinforcing natural sleep-GH positive feedback loop - Patients commonly report more vivid dreams, particularly in first 2-4 weeks - Cognitive clarity improvements reported anecdotally, possibly related to improved sleep architecture and IGF-1 neurotropic effects - No direct CNS receptor activity — all CNS benefits are downstream of GH/IGF-1 elevation ## Integumentary System [Tier 2 - Clinical Observation] - Improved skin elasticity and hydration through IGF-1 stimulated collagen and hyaluronic acid production - Effects typically noticed at 8-12 weeks of consistent use - Hair quality improvement reported by some patients (GH/IGF-1 supports dermal papilla cells) - Nail growth acceleration commonly reported ## Immune System [Tier 3 - Mechanistic] - GH and IGF-1 are immunomodulatory — support thymic function, T-cell proliferation, and NK cell activity - Theoretical immune benefits with long-term physiological GH restoration in aging patients - No direct clinical immune data for CJC-1295 specifically

Practitioner Guide

## Clinical Positioning CJC-1295 no DAC (mod GRF 1-29) is the gold-standard GHRH analog used in peptide therapy clinics. It is ALWAYS prescribed in combination with a GHRP (typically ipamorelin) because the synergy between GHRH + GHRP produces dramatically superior GH release compared to either alone. Prescribing CJC-1295 alone is suboptimal. ## CRITICAL: CJC-1295 no DAC vs. CJC-1295 with DAC - NO DAC (mod GRF 1-29): short-acting, produces natural GH pulses, preserves pulsatility. THIS IS WHAT CLINICS USE. - WITH DAC: drug affinity complex extends half-life to 6-8 days, creates sustained GH elevation (blunted pulsatility), higher IGF-1 elevation, more side effects. NOT recommended for clinical use — it's the version used in the original ConjuChem clinical trials but is pharmacologically quite different. - If a patient says "CJC-1295" without specifying, they almost always mean no DAC (mod GRF 1-29) ## The Saturation Dose Concept - GH secretagogues have a saturation dose — the dose at which maximum GH release per pulse is achieved - For CJC-1295 no DAC, saturation dose is approximately 100mcg (1mcg/kg in a 100kg individual) - Going above saturation dose does NOT increase GH pulse height — it only prolongs the pulse - This means 100mcg and 300mcg produce similar peak GH, but 300mcg extends the pulse duration - Clinical implication: most practitioners dose at 100mcg for efficiency and cost-effectiveness ## Dosing Protocols ### Standard Anti-Aging/Optimization Protocol - CJC-1295 no DAC: 100mcg SC - Ipamorelin: 100-200mcg SC - Combined in the same syringe (both are stable together, no interaction) - Timing: 30-60 minutes before bedtime, FASTED (minimum 2 hours no food) - Frequency: 5 nights/week (weekdays on, weekends off) OR nightly ### Why Fasted at Bedtime - Carbohydrates and fats BLUNT GH release (insulin and free fatty acids suppress GH secretion) - Largest natural GH pulse occurs during first deep sleep cycle - Injecting 30-60 min before sleep synchronizes exogenous pulse with endogenous pulse, creating a supraphysiological additive effect - Protein (amino acids) do NOT blunt GH release and may actually support it — a protein-only snack is acceptable ### Aggressive Recovery Protocol (Post-Injury/Surgery) - CJC-1295 no DAC: 100mcg + Ipamorelin: 200mcg - 2x daily: morning fasted + bedtime fasted - Duration: 4-8 weeks during active healing - Some practitioners add a third midday dose (fasted 2+ hours) for severe injuries ### Long-Term Optimization Protocol - CJC-1295 no DAC: 100mcg + Ipamorelin: 100mcg - Nightly, 5 on/2 off - Cycling: 12 weeks on, 4 weeks off (though many clinics prescribe continuously for years) - The "off" period prevents tachyphylaxis (GH receptor desensitization) though evidence for this is largely theoretical ## Combining in the Same Syringe - CJC-1295 no DAC and ipamorelin can be reconstituted separately and drawn into the same insulin syringe for a single injection - Reconstitution: typically 2mL bacteriostatic water per 2mg vial (1000mcg/mL) - For 100mcg CJC + 200mcg IPA: draw 10 units from CJC vial + 20 units from IPA vial = 30 units total in one syringe - Inject SC in abdominal fat, rotate sites ## What to Expect (Timeline) - Week 1-2: improved sleep quality (often the first noticeable effect), possibly vivid dreams - Week 2-4: improved recovery from workouts, subtle increase in energy and well-being - Week 4-8: body composition changes begin (reduced waist measurement, improved muscle fullness), skin quality improvement - Week 8-16: measurable IGF-1 elevation on bloodwork, continued body composition improvement, hair/nail growth - Month 4-6: full effects realized — improved body composition, sleep, recovery, skin, cognitive clarity - Note: effects are gradual and cumulative, NOT dramatic like exogenous GH. Manage patient expectations. ## Blood Work Protocol Baseline: IGF-1, GH (random or stimulation), fasting glucose, fasting insulin, HbA1c, CBC, CMP Week 6-8: IGF-1 (confirm response — should be elevated but within reference range for age) Month 3: IGF-1, fasting glucose, fasting insulin Ongoing: IGF-1 every 3-6 months Target IGF-1 range: upper tertile of age-adjusted reference range (typically 200-300 ng/mL for adults 30-60) If IGF-1 exceeds reference range: reduce dose or frequency ## Long-Term Safety Observations (from clinics prescribing 5+ years) - No pituitary desensitization observed with continuous use in most patients (some clinics have prescribed for 7+ years continuously) - IGF-1 levels remain stable once equilibrium is reached (no progressive elevation) - No increase in cancer incidence above baseline in clinic patient populations (though controlled data are lacking) - Joint symptoms (carpal tunnel, arthralgias) are rare at physiological doses and indicate IGF-1 is too high — dose reduction resolves - No significant effect on fasting glucose in non-diabetic patients at standard doses - Patients who discontinue after long-term use return to baseline within 2-4 weeks with no withdrawal syndrome ## Common Stacking Partners - Ipamorelin: standard combination (see above) - Sermorelin: sometimes rotated with CJC-1295 no DAC, but adding sermorelin to CJC doesn't add much (both are GHRH analogs competing for the same receptor) - Tesamorelin: may be substituted for CJC in patients specifically targeting visceral fat - BPC-157/TB-500: frequently co-prescribed for injury recovery (BPC-157/TB-500 address tissue repair; CJC/IPA support systemic healing via GH/IGF-1) - MK-677: oral alternative/addition, but lacks the pulsatility of injectable CJC/IPA and has more side effects (hunger, water retention)

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  Growth hormone releasing peptides elevate GH and IGF-1 levels. IGF-1 is a potent mitogen that promotes cell proliferation and inhibits apoptosis, which may accelerate tumor growth and progression in patients with active malignancies.
  Action: Do not use in patients with any active cancer diagnosis. Cancer survivors should obtain oncologist clearance and have IGF-1 levels monitored.
• hard stop — Pregnancy
  No human safety data for CJC-1295 during pregnancy. Supraphysiologic GH/IGF-1 elevation poses theoretical risk to fetal development including macrosomia and developmental abnormalities.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Elevated GH/IGF-1 may affect nursing infant. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use. Exogenous GH stimulation may disrupt normal growth plate physiology and pubertal development.
  Action: Do not provide peptide protocols to individuals under 18. Refer to pediatric endocrinologist.
• requires physician — Diabetes
  Growth hormone elevation antagonizes insulin action and increases hepatic glucose output. May worsen glycemic control in diabetic patients and increase insulin or medication requirements.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Diabetes medication adjustment may be needed. HbA1c monitoring recommended.

Stacks featuring this peptide

Research Summary

## Tier 1 — Human Clinical Data - Modified GRF(1-29) has been studied in multiple human trials for GH deficiency diagnosis and treatment - Single-dose pharmacokinetic studies confirm 2-3x GH amplification above baseline with a 30-minute half-life - Combined GHRH + GHRP studies in humans show synergistic GH release 3-10x greater than either peptide alone (Bowers et al., multiple studies) - Sermorelin (parent compound GRF 1-29 without modifications) was FDA-approved, establishing the mechanism's clinical validity - The four amino acid substitutions (Ala2→D-Ala, Asn8→Gln, Ala15→Ala(Me), Met27→Leu) confer DPP-IV resistance without altering receptor binding ## Tier 2 — Clinical Observation Data - Thousands of patients have been treated with CJC-1295 no DAC + ipamorelin in anti-aging and optimization clinics since ~2015 - Clinic-level data (non-controlled) consistently show: IGF-1 elevation of 30-80%, improved body composition, improved sleep quality, improved recovery metrics - Adverse events at standard doses are rare: occasional injection site irritation, transient facial flushing, rare headache - Tachyphylaxis (reduced response over time) has NOT been consistently observed even with continuous use, contradicting theoretical concerns ## Tier 3 — Preclinical/Mechanistic - GHRH receptor (GHRH-R) binding kinetics well-characterized: mod GRF 1-29 has equivalent affinity to native GHRH(1-44) at the receptor - Four amino acid substitutions prevent DPP-IV cleavage at position 2, extending the half-life from ~7 minutes to ~30 minutes - Does not cross-react with GHS-R (ghrelin receptor), confirming mechanism is purely GHRH-mediated - Synergy with GHRP is mechanistically explained: GHRH stimulates cAMP/PKA pathway on somatotrophs while GHRP activates IP3/DAG pathway — convergent but non-redundant signaling ## Evidence Gaps - No large-scale Phase III RCTs for CJC-1295 no DAC specifically (clinical trials used the DAC version or sermorelin) - Long-term cancer safety data limited to observational clinic data (no prospective controlled studies) - Optimal cycling protocols (continuous vs. intermittent) not studied in controlled trials - Dose-response relationship in humans not rigorously defined beyond single-dose PK studies - Comparative efficacy vs. low-dose exogenous GH not established in controlled trials